行情

CBIO

CBIO

Brookfield再生能源
NASDAQ

实时行情|Nasdaq Last Sale

7.38
+0.06
+0.82%
休市 16:00 01/17 EST
开盘
7.32
昨收
7.32
最高
7.48
最低
7.23
成交量
15.38万
成交额
--
52周最高
10.84
52周最低
4.520
市值
8,886.14万
市盈率(TTM)
-1.6874
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CBIO 新闻

  • 蛋壳公寓闯关IPO 上市后盈利痛点更受关注
  • 一财网.1小时前
  • 成功登陆美股!蛋壳公寓如何讲好“新租赁”故事
  • 东方财富网.2小时前
  • Lululemon:谜题待解
  • 界面.4小时前
  • 复飞之路再现波折 波音737Max软件又曝新缺陷
  • 中国新闻网.5小时前

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

CBIO 简况

Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company's advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.
展开

Webull提供Catalyst Biosciences Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。